总部位于德国的费森尤斯医疗(Fresenius Medical Care)于3月29日同意支付约2.31亿美元，用于了结美国司法部（DOJ）和美国证券交易监督委员会（简称：美国证监会，SEC）对其联合提出的行贿指控，因为该公司为赢得13个国家的业务采用了各种行贿手段。

2007年至2016年期间，自称是全球优秀的慢性肾衰竭治疗产品和服务提供商的费森尤斯承认向公共卫生和/或政府官员行贿，为的是获得或保留在多个国家的业务，包括安哥拉、沙特阿拉伯、摩洛哥、西班牙、土耳其和西非国家。

2008年至2011年期间，在未签署咨询协议或合同的情况下，弗雷森尤斯向一名西班牙公职医生支付了8.1万多欧元（9.1万美元）的费用。这位医生是西班牙一家国有医院的肾脏科主任，他在2011年向费森尤斯授予了一份投标书。  

美国司法部表示:“费森尤斯还通过一个冒牌委员会向一名摩洛哥政府官员行贿，为的是拿下在摩洛哥国有军事医院开发肾脏透析中心的合同。”

美国司法部还表示，费森尤斯与土耳其公职医生成立了合资企业，这些医生将业务从公共雇主转到土耳其的费森尤斯诊所。

费森尤斯还贿赂了西非国家的公共卫生官员和政府雇佣医生，包括贝宁、布基纳法索、喀麦隆、科特迪瓦、尼日尔、加蓬、乍得和塞内加尔。  

美国司法部发现，费森尤斯在13个国家的贿赂行为为其产生了逾1.4亿美元的利润。

尽管费森尤斯在2012年4月主动披露了自身的不当贿赂行为，但美国司法部表示，该公司没有对某些请求做出及时回应，有时也没有对请求作出充分回应。“此外，该公司尚未有机会检验其合规性增强措施的有效性，”司法部表示。

Fresenius to Pay $231M to Resolve Foreign Bribery Charges

Germany-based Fresenius Medical Care on Friday agreed to pay about $231 million to resolve investigations by the Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) because of Fresenius’s participation in various bribery schemes to win business in 13 countries.

Between 2007 and 2016, Fresenius, which describes itself as the world’s leading provider of products and services for people with chronic kidney failure, admitted to paying bribes to publicly-employed health and/or government officials to obtain or retain business in multiple countries, including Angola, Saudi Arabia, Morocco, Spain, Turkey and countries in West Africa.

In Spain, between 2008 and 2011, Fresenius paid a publicly employed doctor more than €81,000 ($91,000) without a consulting agreement or contract. The doctor, the head of nephrology at a Spanish state-owned hospital, awarded Fresenius a tender in 2011.  

“In Morocco, Fresenius paid bribes through a sham commission to a Moroccan state official for the purpose of obtaining contracts to develop kidney dialysis centers at Moroccan state-owned military hospitals,” the DOJ said.

In Turkey, the DOJ said Fresenius entered into joint ventures with publicly-employed doctors who directed business from their public employer to Fresenius clinics in Turkey.

Fresenius also bribed publicly-employed health officials and government-employed doctors in West African countries, including Benin, Burkina Faso, Cameroon, the Ivory Coast, Niger, Gabon, Chad and Senegal.  

DOJ found the misconduct across the 13 countries yielded profits of more than $140 million.

And although Fresenius did voluntarily self-disclose the misconduct in April 2012, the DOJ said the company did not offer timely responses to certain requests and sometimes did not provide full responses to requests. “Moreover, the company has not yet had the opportunity to test the effectiveness of its compliance enhancements,” DOJ said.

来源：RAPS

原文链接：https://www.raps.org/news-and-articles/news-articles/2019/3/fresenius-to-pay-231m-to-resolve-foreign-bribery

整理翻译：奥咨达